Advertisement

Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81
Organisation › Details

Pila Pharma AB

PILA PHARMA is a Swedish pharmaceutical company in the diabetes segment based in Malmö. The aim of the company is to develop a novel and superior tablet based treatment for type 2 diabetes. The company owns both use patents for treating diabetes and obesity with TRPV1 antagonists, and the intellectual property rights for the mid stage clinical development candidate XEN-D0501. About XEN-D0501 and TRPV1 antagonists XEN-D0501 is a highly selective and very potent small molecule TRPV1 antagonist, previously in development by Bayer Healthcare and Xention/ Ario Pharma. The TRPV1 target (also called the “chili-receptor”) has demonstrated applications across pain and inflammatory diseases and potentially plays a role in diabetes as well. XEN-D0501 was acquired by PILA PHARMA in March 2016, due to its very good safety and tolerability as compared to other clinical TRPV1-antagonist development candidates. TRPV1 antagonists as a drug-class has previously been associated with severe adverse events as fever (hyperthermia). XEN-D0501 has in healthy volunteers been shown to induce a modest temperature increase following the first dose, that fades out during the first 2 weeks of dosing. The maximal tolerable dose in non-diabetic individuals has previously been determined to be 4 milligrams twice daily, a dose level with good safety but no effect in non-diabetic patients with either overactive bladder disease or chronic cough. In November 2018, PILA PHARMA reported the completion of its first clinical trial, PP-CT01, demonstrating good safety of XEN-D0501 at single doses up to 8 milligrams when administered to people with type 2 diabetes. *

 

Period Start 2014-01-01 established
Products Industry antidiabetic
  Industry 2 obesity drug
Persons Person Gram, Dorte X. (Pila Pharma 201912 CEO + Founder)
  Person 2 Rasmussen, Lars Bukhave (Pila Pharma 202009– CFO before Leo Pharma)
     
Region Region Malmö
  Country Sweden
  Street 1 Västergatan
  City 21121 Malmö
    Address record changed: 2020-11-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Pila Pharma AB. (9/24/20). "Press Release: Pila Pharma Announces Positive Phase 2a Results in People with Type 2 Diabetes and Strengthening of the Organization". Malmö.
     
   
Record changed: 2020-09-27

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Pila Pharma AB


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81




» top